These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Percutaneous Left Atrial Appendage Occlusion in Comparison to Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation. Noseworthy PA; Van Houten HK; Krumholz HM; Kent DM; Abraham NS; Graff-Radford J; Alkhouli M; Henk HJ; Shah ND; Gersh BJ; Friedman PA; Holmes DR; Yao X J Am Heart Assoc; 2022 Oct; 11(19):e027001. PubMed ID: 36172961 [TBL] [Abstract][Full Text] [Related]
6. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644 [TBL] [Abstract][Full Text] [Related]
7. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies. Li X; Wen SN; Li SN; Bai R; Liu N; Feng L; Ruan YF; Du X; Dong JZ; Ma CS Heart Rhythm; 2016 Jun; 13(6):1203-14. PubMed ID: 26724488 [TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. Zhou Y; He W; Zhou Y; Zhu W J Thromb Thrombolysis; 2020 Aug; 50(2):311-317. PubMed ID: 31792707 [TBL] [Abstract][Full Text] [Related]
9. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Chew DS; Zhou K; Pokorney SD; Matchar DB; Vemulapalli S; Allen LA; Jackson KP; Samad Z; Patel MR; Freeman JV; Piccini JP Ann Intern Med; 2022 Sep; 175(9):1230-1239. PubMed ID: 35969865 [TBL] [Abstract][Full Text] [Related]
10. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis. Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of left atrial appendage closure procedure in patients with non-valvular atrial fibrillation with contraindication and/or failure for oral anticoagulants: A systematic review and meta-analysis. Simões RDS; Bortoluzzi AFR; Marinho JCN; Galendi JSC; Bernardo WM Clinics (Sao Paulo); 2024; 79():100465. PubMed ID: 39216123 [TBL] [Abstract][Full Text] [Related]
12. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation. Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Chan YH; Lee HF; Li PR; Liu JR; Chao TF; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH Cardiovasc Diabetol; 2020 May; 19(1):63. PubMed ID: 32404168 [TBL] [Abstract][Full Text] [Related]
14. Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results. Litwinowicz R; Bartus M; Kapelak B; Suwalski P; Lakkireddy D; Lee RJ; Bartus K Catheter Cardiovasc Interv; 2019 Nov; 94(6):837-842. PubMed ID: 30884101 [TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis. Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052 [TBL] [Abstract][Full Text] [Related]
16. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN. Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282 [TBL] [Abstract][Full Text] [Related]
17. Percutaneous left atrial appendage occlusion in mitral valve disease: A Nationwide Readmission Database analysis. Feroze R; Ullah W; Kang P; Lobo T; Alhabdan N; Alghammass M; Yoon SH; Dallan LAP; Filby SJ Cardiovasc Revasc Med; 2024 Jun; 63():23-30. PubMed ID: 38267285 [TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103 [TBL] [Abstract][Full Text] [Related]
19. Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Korsholm K; Damgaard D; Valentin JB; Packer EJS; Odenstedt J; Sinisalo J; Putaala J; Næss H; Al-Jazi MA; Karlsson JE; Pontoppidan J; Modrau B; Hjort J; Matzen KL; Johnsen SP; Nielsen-Kudsk JE Am Heart J; 2022 Jan; 243():28-38. PubMed ID: 34537184 [TBL] [Abstract][Full Text] [Related]
20. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]